| Microorganism |
MIC50
(μg/ml) |
MIC90
(μg/ml) |
Range
(μg/ml) |
Antimicrobial |
Reference |
| Staphylococcus hominis (coagulase-negative + oxacillin-resistant) |
≤32 |
≤256 |
≤2 － >256 |
Mupirocin (Bactroban)  |
592 |
| Staphylococcus hominis (coagulase-negative + oxacillin-resistant) |
>100 |
>100 |
≤0.12 － >100 |
Clindamycin (Cleocin) |
592 |
| Staphylococcus hominis (coagulase-negative + oxacillin-resistant) |
>200 |
>200 |
≤0.12 － >200 |
Erythromycin (E-mycin, Ery-tab, Benzamycin) |
592 |
| Staphylococcus hominis (coagulase-negative + oxacillin-susceptible) |
0.12 |
0.25 |
≤0.06 － >8 |
Clindamycin (Cleocin) |
412 |
| Staphylococcus hominis (coagulase-negative + oxacillin-susceptible) |
0.12 |
2 |
≤0.03 － >4 |
Gatifloxacin (Tequin) |
412 |
| Staphylococcus hominis (coagulase-negative + oxacillin-susceptible) |
>0.25 |
>2 |
0.06 － >2 |
Ciprofloxacin (Cipro, Ciproxin, Ciprobay) |
412 |
| Staphylococcus hominis (coagulase-negative + oxacillin-susceptible) |
≤0.5 |
≤0.5 |
≤0.5 － >8 |
Imipenem |
412 |
| Staphylococcus hominis (coagulase-negative + oxacillin-susceptible) |
0.5 |
1 |
≤0.5 － 8 |
Zosyn |
412 |
| Staphylococcus hominis (coagulase-negative + oxacillin-susceptible) |
0.5 |
2 |
≤0.12 － 8 |
Cefepime (Maxipime) |
412 |
| Staphylococcus hominis (coagulase-negative + oxacillin-susceptible) |
>0.5 |
>2 |
≤0.5 － >2 |
Co-trimoxazole (Trimethoprim-sulfamethoxazole, TMP-SMX) |
412 |
| Staphylococcus hominis (coagulase-negative + oxacillin-susceptible) |
1 |
2 |
≤0.12 － 4 |
Vancomycin (Vancocyn, Lyphocin) |
412 |
| Staphylococcus hominis (coagulase-negative + oxacillin-susceptible) |
2 |
4 |
≤0.25 － >32 |
Ceftriaxone (Rocephin) |
412 |
| Staphylococcus hominis (coagulase-negative + oxacillin-susceptible) |
4 |
8 |
0.25 － >16 |
Ceftazidime (Ceptaz, Fortaz, Tanicef) |
412 |
| Staphylococcus hominis (coagulase-negative) |
0.06 |
2 |
≤0.06 － >256 |
Rifampicin (Rifampin) |
497 |
| Staphylococcus hominis (coagulase-negative) |
0.06 |
64 |
≤0.06 － 128 |
Gentamicin (Gentamycin, Garamycin) |
497 |
| Staphylococcus hominis (coagulase-negative) |
0.125 |
0.25 |
≤0.06 － 1 |
Quinupristin/Dalfopristin (Synercid) |
497 |
| Staphylococcus hominis (coagulase-negative) |
0.125 |
0.5 |
≤0.06 － 0.5 |
Tigecycline (GAR-936, Tigacyl) |
497 |
| Staphylococcus hominis (coagulase-negative) |
0.25 |
0.5 |
0.125 － 1 |
Linezolid (PNU-100766, U-100766, Zyvox) |
497 |
| Staphylococcus hominis (coagulase-negative) |
0.25 |
8 |
≤0.06 － 128 |
Levofloxacin (Levaquin, Quixin) |
497 |
| Staphylococcus hominis (coagulase-negative) |
1 |
1 |
0.5 － 2 |
Vancomycin (Vancocyn, Lyphocin) |
497 |
| Staphylococcus hominis (coagulase-negative) |
1 |
4 |
0.25 － 8 |
Teicoplanin (Targocid) |
497 |
| Staphylococcus hominis (F10) |
- |
- |
15.62 － ? |
Sulbactam |
176 |
| Staphylococcus hominis (F10) |
- |
- |
62.5 － ? |
Satureja hortensis (Summer savory) (Essential oil) |
1344 |
| Staphylococcus hominis (F10) |
- |
- |
125 － ? |
Cefepime hydrochloride (Maxipime) |
1344 |
| Staphylococcus hominis (LQC 5012) |
- |
- |
2 － ? |
Ampicillin (Omnipen) |
836 |
| Staphylococcus hominis (LQC 5012) |
- |
- |
2 － ? |
Erythromycin (E-mycin, Ery-tab, Benzamycin) |
836 |
| Staphylococcus hominis (LQC 5012) |
- |
- |
8 － ? |
Chloramphenicol (Chloromycetin) |
836 |
| Staphylococcus hominis (LQC 5012) |
- |
- |
8 － ? |
Tetracycline (Sumycin, Achromycin V, Steclin) |
836 |